Upacicalcet 在血液透析继发性甲状旁腺功能亢进患者中的疗效与安全性:两项随机临床试验
两项设计相同的 3 期双盲安慰剂对照试验(PATH-1 与 PATH-2)纳入 768 例血清 iPTH 400–1500 pg/ml 的血液透析继发性甲旁亢患者,随机接受静脉 upacicalcet(n=510)或安慰剂(n=258)27 周。upacicalcet 组达到 iPTH 较基线下降 ≥30% 的比例显著高于安慰剂,无症状低钙血症和剂量中断更常见,症状性低钙血症少见,胃肠道事件与安慰剂相似。
要点
- upacicalcet 显著提高血液透析继发性甲旁亢患者 iPTH 下降 ≥30% 的达标比例。
- 无症状低钙血症与剂量中断较安慰剂更常见,症状性低钙血症少见。
- 胃肠道不良事件发生率与安慰剂相似,严重不良事件两组相近。
核心结论
- 两项 3 期试验中 upacicalcet 较安慰剂显著降低血液透析继发性甲旁亢患者的 iPTH。
- upacicalcet 组无症状低钙血症和剂量中断更常见,症状性低钙血症少见,胃肠道不良事件与安慰剂相似。
研究设计与样本
- PATH-1 和 PATH-2 为设计相同、随机、3 期、双盲、安慰剂对照试验,平行开展。
- 共纳入 768 例接受血液透析、血清 iPTH ≥400 至 ≤1500 pg/ml 的继发性甲旁亢患者。
- 参与者接受静脉 upacicalcet(n=510)或安慰剂(n=258)透析后给药 27 周,依据 iPTH 和校正血钙滴定剂量。
- 主要终点为疗效评估期(第 22–27 周)平均 iPTH 较基线下降 ≥30% 的参与者比例。
主要发现
- PATH-1 中主要终点达成比例 upacicalcet 组 42.1% 对安慰剂组 16.8%,率差 25.3%(95%CI 16.2–34.5,P<0.001)。
- PATH-2 中主要终点达成比例 upacicalcet 组 43.5% 对安慰剂组 17.4%,率差 26.1%(95%CI 17.4–34.8,P<0.001)。
- 严重不良事件两组相近:PATH-1 为 26% 对 24%,PATH-2 为 23% 对 22%。
- 校正血钙 <7.5 mg/dl 在 PATH-1 为 31% 对 12%、PATH-2 为 45% 对 19%;剂量中断分别为 44% 对 24% 和 52% 对 27%。
- 研究者判定的症状性低钙血症在 upacicalcet 组分别为 0.8% 和 2%,安慰剂组无报告。
关键数值与推荐
- 入组条件:血液透析伴继发性甲旁亢且血清 iPTH ≥400 至 ≤1500 pg/ml。
- 主要终点阈值:疗效评估期(第 22–27 周)平均 iPTH 较基线下降 ≥30%。
- 校正血钙 <8.3 mg/dl 且无低钙症状时,限制补钙或更改活性维生素 D 甾体。
临床怎么用
- upacicalcet 可作为血液透析继发性甲旁亢降低 iPTH 的静脉拟钙剂选择。
- 用药期间需监测校正血钙,警惕无症状低钙血症及因此导致的剂量中断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: These 2 phase 3 trials assessed upacicalcet, an intravenous calcimimetic, in hemodialysis patients with secondary hyperparathyroidism. ≥30% reduction in intact parathyroid hormone levels occurred in 42% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-1) and 44% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-2) with upacicalcet versus 17% and 17%, respectively, with placebo (strata-adjusted; both P < 0.001). Asymptomatic hypocalcemia was more frequent with upacicalcet, and symptomatic hypocalcemia was infrequent; gastrointestinal events were similar to placebo. BACKGROUND: Secondary hyperparathyroidism is a common complication in patients with CKD undergoing hemodialysis. We examined the efficacy and safety of upacicalcet, an intravenous calcimimetic, versus placebo on serum intact parathyroid hormone (iPTH) levels in patients receiving hemodialysis. METHODS: Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis (PATH)-1 and PATH-2 were identical, randomized, phase 3, double-blind, placebo-controlled trials conducted in parallel in 768 patients receiving hemodialysis with secondary hyperparathyroidism and serum iPTH levels ≥400 to ≤1500 pg/ml. Participants received intravenous upacicalcet ( n =510) or placebo ( n =258) after hemodialysis for 27 weeks; dosing was titrated using iPTH and corrected serum calcium. Calcium supplementation or changes in active vitamin D sterols for corrected serum calcium <8.3 mg/dl without hypocalcemia symptoms were restricted. The primary outcome was the proportion of participants achieving ≥30% decrease from baseline in mean iPTH during the efficacy assessment period, weeks 22-27. RESULTS: The strata-adjusted proportions of participants achieving the primary outcome were significantly higher with upacicalcet versus placebo: in PATH-1, 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001); in PATH-2, 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001). Serious adverse events were similar between upacicalcet and placebo (PATH-1, 26% versus 24%; PATH-2, 23% versus 22%). Rates of gastrointestinal symptoms were similar between treatment groups. Corrected calcium <7.5 mg/dl occurred in 31% versus 12% in PATH-1 and 45% versus 19% in PATH-2; dose interruptions occurred in 44% versus 24% and 52% versus 27%, respectively. Investigator-attributed symptomatic hypocalcemia was reported in 0.8% and 2% of upacicalcet-treated participants, respectively, and in no placebo patients. CONCLUSIONS: In 2 phase 3 trials, upacicalcet significantly reduced iPTH versus placebo. Asymptomatic hypocalcemia and dose interruptions were more frequent in patients receiving upacicalcet, while symptomatic hypocalcemia was infrequent and gastrointestinal adverse event rates were similar to placebo. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: PATH-1 NCT05832931 and PATH-2 NCT05836220 .
引用
- Kendrick J, Ketteler M, Wolf M, et al. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: Two Randomized Clinical Trials. J Am Soc Nephrol. 2026. PMID: 42914959. doi:10.1681/ASN.0000001285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。